Why Teva’s Dip on Earnings Is an Opportunity
Chuck Carnevale submits:
Teva, headquartered in Petach Tikva, Israel, is the world’s largest generic drug company and trades as an ADR under the symbol (TEVA). The company reported earnings Tuesday that were in fact up strongly on strong revenue growth exceeding 30%, and it also raised its dividend by 17%. [Read Teva's Q409 earnings call transcript here.] Yet interestingly, the stock was down on an up day. This is due to Teva’s missing analyst expectations by a mere penny. Oh, the peculiar illogic of Wall Street.
Let’s look at this above-average consistent earnings grower from the perspective of our F.A.S.T.™ graphs (Fundamentals Analyzer Software Tool) with figure 1 below plotting earnings only.
Investing, Long Term Investment, stock market | admin February 17, 2010
RSS feed for comments on this post.
